ESYDROX KID/250

Main information

Trade name:
ESYDROX KID/250 10 TAB

Available from:
Espee Form.

Pharmaceutical form:
TAB

Composition:
10

Medicine domain:
Humans

Medicine type:
Allopathic drug

Documents

for the general public:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

for healthcare professionals:
The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for healthcare professionals.

Localization

Available in:
India

Language:
English

Other information

Status

Source:
Central Drugs Standard Control Organization

Last update:
09-08-2016

The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.

Request the information leaflet for the general public.

Access to this document is only available to registered users.

Register now for full access

1-3-2018

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

February 28, 2018: Two Doctors Arrested Pursuant to Federal Indictment That Alleges Bogus Sleep Studies Helped 1-800-Get-Thin Fraudulently Bill Insurance Programs Over $250 Million Related to Lap-Band Surgeries

FDA - U.S. Food and Drug Administration

18-1-2018

Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall - Presence of Visible Particulate Matter

Use of a non-sterile injectable product could result in fatal infections.

FDA - U.S. Food and Drug Administration

18-1-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Levofloxacin in 5% Dextrose 250mg/50mL Due to Presence of Visible Particulate Matter Tentatively Identified as Mold

FOR IMMEDIATE RELEASE – 01-12-2018 – East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling one lot of Levofloxacin in 5% Dextrose Injection 250mg/50mL in a Single-Use flexible container NDC 55150-243-46, Lot CLF160003, Expiry date May 2018, to the hospital level. The product has been found to contain visible particulate matter tentatively identified as mold. This problem was discovered as a result of a product complaint in which the contents of one flexible bag was found to contain whi...

FDA - U.S. Food and Drug Administration

5-7-2017

Voluntary Recall of CLIF BUILDER'S Bar Chocolate Mint Flavor, CLIF Kid Zbar Protein Chocolate Mint and CLIF Kid Zbar Protein Chocolate Chip Flavors

Clif Bar & Company is initiating a voluntary recall of CLIF® BUILDER'S® Bar Chocolate Mint flavor, and CLIF Kid Zbar® Protein Chocolate Mint and CLIF Kid Zbar® Protein Chocolate Chip flavors due to possible presence of undeclared peanuts and some tree nuts, including almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, walnuts and coconuts. Clif Bar & Company is taking this precautionary safety step for people who are allergic to peanuts and these listed tree nuts. People with an allergy to ...

FDA - U.S. Food and Drug Administration

31-1-2018

Scientific guideline: Draft cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, draft: consultation open

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

30-1-2018

ENDURE 250 (Triclosan) Solution [Ecolab Inc.]

Updated Date: Jan 30, 2018 EST

US - DailyMed

17-1-2018

Mvasi (Amgen Europe B.V.)

Mvasi (Active substance: bevacizumab) - Centralised - Authorisation - Commission Decision (2018)250 of Wed, 17 Jan 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4728

Europe -DG Health and Food Safety

29-12-2017